Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Valencia

PharmaDeviceNews Valencia

Medical Devices & Diagnostics

Why Quanta System’s ICE26 award comes at a crucial moment for its surgical laser business

by Pallavi Madhiraju
October 11, 2026
0 Comments

Quanta System's ICE26 recognition brings its urology lasers, clinical evidence, US expansion and 2027 development plans into focus.

Read More

Latest news and features

World ADC 2026 highlights Invenra’s approach to HER2 and HER3 targeting
Fujifilm’s new pathology AI can classify tissue changes, but is it ready for cancer diagnosis?
Can Insulet’s new diabetes data platform improve time in range and patient engagement?
What the ALOFT-IPF results mean for Bristol Myers Squibb and pulmonary fibrosis treatment
Brent Saunders exits Bausch + Lomb just as earnings improve. What changes under Thomas Appio?
Bristol Myers Squibb’s $4.1bn RayzeBio acquisition delivers clinical milestone
Can Teleflex’s Freesolve scaffold challenge permanent drug-eluting stents?
Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis
Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement
Perceive Biotherapeutics completes VOY-101 Phase 2a JOURNEY enrollment in geographic atrophy
Why Thermedical’s Durablate catheter could address difficult-to-reach heart arrhythmias
Kyowa Kirin Poteligeo MINT study shows 62.4% response in cutaneous T-cell lymphoma

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Elevra secures a major LG lithium contract, but why does pricing remain the biggest risk?
Stakk (ASX: SKK) posts 16.5% quarterly revenue growth after ParaScript acquisition
Frasers saved more than 1,000 Harvey Nichols jobs. Why are closures starting only weeks later?
Krystal plans 10,000 jobs across India. Can margins keep pace with such rapid workforce expansion?
CEMEX is saving $475m globally. What does the Lyons workforce cut reveal about its asset strategy?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.